92%
Finnrick rating
#1 of 250 Retatrutide vendors
24 of 25 classifiable tests passed
natural 96% · customers 4.6★ (19)
methodology · Purity focus
Finnrick analysis · Retatrutide

Peptide Partners Retatrutide has a notable caveat despite a strong purity-focus signal: a Nov 2025 purity miss at 99.11% and fill swings to -21% and +22%. Recent tests show a rebound with identity passes and documented batches.

methodology →
vendor intelligence report
Vendor Intelligence Report: Peptide Partners

Policies name Pirsek Technologies and Wyoming law, but registry searches leave the entity chain partly open. The full briefing maps Zak David’s public operator trail, the Shopify-to-WooCommerce migration, referral-code network, Trustpilot removal, and COA/lab controls.

27 pages7 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutideselected
$4.85
92%
25
2
GHK-Cu
$0.75
91%
4
3
Ipamorelin
$3.74
85%
8
4
Tirzepatide
$2.31
80%
7
5
BPC-157
$5.30
55%
10
6
Tesamorelin
$4.95
47%
12
7
CJC-1295
$4.50
36%
9
8
TB-500
$4.90
33%
13
Contact channels
Vendor policies

Batch identification policy

All vial labels have a Batch Id that can be reconciled against the various COAs for Purity/Assay, Endotoxin, Heavy Metals, or Sterility testing at

Sample authentication guidance

Our 3mL vials have a 1.25" x 0.75" white, BOPP label. At the top of the label is the full logo with the 'P Vial' symbol on the left, followed Peptide Partners, and underneath it says "CONNECTING THE GLOBAL RESEARCH COMMUNITY." Underneath the logo is a line identifying the molecule and weight. Underneath that is the word 'Batch' followed by an identification code. At the bottom of the label it reads "Research Use Only"

Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%17 Nov 2025: 82%26 Jan 2026: 84%29 Jan 2026: 85%22 Feb 2026: 86%1 Mar 2026: 87%2 Mar 2026: 88%2 Mar 2026: 88%3 Mar 2026: 89%23 Apr 2026: 90%28 Apr 2026: 90%8 May 2026: 91%12 Jun 2026: 91%16 Jun 2026: 92%4 Aug 2026: 92%5 Aug 2026: 92%9 Aug 2026: current 92%82%86%92%Nov 25Aug 26
Showing Retatrutide tests only
Peptide Partners Retatrutide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
5 Aug 2026Pass
Tested
lab nameView COA
4 Aug 2026Pass
Tested
lab nameView COA
16 Jun 2026Pass
Tested
lab nameView COA
12 Jun 2026Pass
Tested
lab nameView COA
8 May 2026Pass
Tested
lab nameView COA
28 Apr 2026Pass
Tested
lab nameView COA
23 Apr 2026Pass
Tested
lab nameView COA
3 Mar 2026Pass
Tested
lab nameView COA
2 Mar 2026Pass
Tested
lab nameView COA
2 Mar 2026Pass
Tested
lab nameView COA
1-10 of 25

About Peptide Partners test results from Finnrick

Peptide Partners is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 8 peptides and 88 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Peptide Partners peptides in this dataset are Retatrutide (25 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 88 recent tests.

Corrections
No corrections.